Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the twenty stocks on our list of best biotech stocks is Kura Oncology, Inc.

TheFly reported on January 13 that Leerink Partners lowered the price target on KURA to $20 from $25 and maintained an Outperform rating. This revision reflects updates to the model incorporating preliminary Q4 financial results, which include Komzifti’s net product revenue, collaboration revenue, and 2026 guidance ahead of the company’s Q4 earnings report.

In addition, Kura Oncology, Inc. (NASDAQ:KURA) disclosed on January 11 that KOMZIFTI (ziftomenib) generated $2.1 million in net product sales during the first five weeks of commercial availability, which ended on December 31, 2025. The first oral menin inhibitor approved for use once daily in patients with refractory or relapsed NPM1-mutated acute myeloid leukemia (AML) is called KOMZIFTI.

The business recognized advancements in all of its TSHA-102 development programs and outlined anticipated 2026 milestones. These accomplishments included expanding ziftomenib into combination regimens and non-AML indications, increasing the commercial usage of KOMZIFTI, and progressing current AML clinical investigations.

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical‑stage biopharmaceutical company discovering and developing targeted therapies for cancer and hematologic malignancies. Its pipeline includes precision small‑molecule inhibitors aimed at key oncogenic drivers, to deliver effective, well‑tolerated treatments that improve patient outcomes in genetically defined cancer populations.

While we acknowledge the potential of KURA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.